"Buspirone: a clinical review of a new, non-benzodiazepine anxiolytic".
This discussion deals with several issues of potential importance in making refined comparisons between buspirone and reference drugs as to their relative sedative and antianxiety effects (cost/benefit analyses). Factors considered that may influence the balance of sedative and antianxiety effects include drug dose, initial level of anxiety, environmental contingencies, and criteria for sedation. Additional studies of buspirone are suggested, with special reference to depression and aggression, to explore further some of the properties observed in the clinical trials presented at this symposium on "Buspirone: A Clinical Review of a New, Non-Benzodiazepine Anxiolytic."
D014151:Anti-Anxiety Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000188:drug therapy / Q000523:psychology; D001143:Arousal / Q000187:drug effects; D002065:Buspirone; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D004305:Dose-Response Relationship, Drug; D006801:Humans; D011597:Psychomotor Performance / Q000187:drug effects; D011743:Pyrimidines / Q000494:pharmacology* / Q000627:therapeutic use
D014151:Anti-Anxiety Agents; D011743:Pyrimidines; D002065:Buspirone